Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

$459.00 -3.58 (-0.77%)

Closing price 02/14/2025 04:00 PM Eastern

Extended Trading

$455.32 -3.68 (-0.80%)

As of 02/14/2025 07:58 PM Eastern

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
0

Hold
10

Buy
16

Based on 26 Wall Street analysts who have issued ratings for Vertex Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 10 have given a hold rating, 15 have given a buy rating, and 1 has given a strong buy rating for VRTX.

Consensus Price Target

$505.57
10.14% Upside

According to the 26 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $505.57. The highest price target for VRTX is $586.00, while the lowest price target for VRTX is $407.00. The average price target represents a forecasted upside of 10.14% from the current price of $459.00.

Get the Latest News and Ratings for VRTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors.

VRTX Analyst Ratings Over Time

Type	Current Forecast 2/16/24 to 2/15/25	1 Month Ago 1/17/24 to 1/16/25	3 Months Ago 11/18/23 to 11/17/24	1 Year Ago 2/16/23 to 2/16/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	15 Buy rating(s)	17 Buy rating(s)	17 Buy rating(s)	12 Buy rating(s)
Hold	10 Hold rating(s)	10 Hold rating(s)	9 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$505.57	$490.38	$499.12	$417.27
Forecasted Upside	10.14% Upside	17.61% Upside	7.18% Upside	-1.17% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

VRTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Vertex Pharmaceuticals Stock vs. The Competition

Type	Vertex Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.67	2.82	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	10.23% Upside	27,119.81% Upside	13.59% Upside
News Sentiment Rating	Positive News See Recent VRTX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/11/2025	Canaccord Genuity Group 1 of 5 stars	Whitney Ijem Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Hold	$408.00 ➝ $424.00	-7.59%
2/11/2025	Truist Financial 2 of 5 stars	Joon Lee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$460.00 ➝ $520.00	+13.01%
2/11/2025	Royal Bank of Canada 4 of 5 stars	Brian Abrahams Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Perform ➝ Sector Perform	$402.00 ➝ $407.00	-11.36%
2/11/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Gena Wang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$435.00 ➝ $467.00	+1.35%
2/11/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Olivia Brayer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$480.00 ➝ $480.00	+4.17%
2/11/2025	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Perform ➝ Sector Perform	$433.00 ➝ $450.00	-2.34%
2/11/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
2/11/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$450.00 ➝ $459.00	-2.33%
2/11/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Fein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$550.00 ➝ $550.00	+17.03%
1/31/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
Get the Latest News and Ratings for VRTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
1/30/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$460.00 ➝ $460.00	+4.19%
1/27/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Christopher Raymond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$535.00 ➝ $533.00	+20.72%
12/23/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$503.00 ➝ $500.00	+25.86%
12/20/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$566.00 ➝ $520.00	+32.36%
12/19/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
12/19/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$545.00 ➝ $522.00	+34.41%
12/16/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$490.00 ➝ $494.00	+6.53%
12/9/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$500.00 ➝ $550.00	+19.02%
11/14/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$575.00	+16.25%
11/5/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Bristow Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$562.00 ➝ $586.00	+17.77%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
8/2/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$450.00 ➝ $558.00	+13.08%
7/23/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$450.00 ➝ $500.00	+1.60%
6/27/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Chesney Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$545.00	+14.98%
6/17/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$465.00 ➝ $550.00	+15.48%
4/11/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	In-Line ➝ Outperform	$438.00	+10.17%
2/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$515.00	+23.24%
2/2/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
1/31/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$325.00	-25.27%
1/31/2024	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
6/26/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
5/25/2023	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:08 AM ET.

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, February 4, 2025. Please send any questions or comments about these Vertex Pharmaceuticals pros and cons to contact@marketbeat.com.

Vertex Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

Vertex Pharmaceuticals Incorporated has recently reported strong earnings, with an earnings per share (EPS) of $4.38, surpassing analysts' expectations of $3.61. This indicates robust financial performance and potential for future growth.
The stock price of Vertex Pharmaceuticals Incorporated is currently at $482.55, reflecting a 2.6% increase in recent trading. A rising stock price can signal investor confidence and market interest.
Analysts have a consensus rating of "Moderate Buy" for Vertex Pharmaceuticals Incorporated, with a target price averaging $502.58. This suggests that many analysts believe the stock has room for growth.
Vertex Pharmaceuticals Incorporated has a strong market presence in the biotechnology sector, particularly in developing therapies for cystic fibrosis, which positions the company well for continued revenue growth.
Institutional investors hold 90.96% of the stock, indicating strong confidence from large financial entities, which can be a positive signal for individual investors.

Vertex Pharmaceuticals
Bear Case

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

Despite recent earnings growth, Vertex Pharmaceuticals Incorporated has a negative net margin of 4.52%, which indicates that the company is currently spending more than it earns, raising concerns about long-term profitability.
The stock has a high price-to-earnings (P/E) ratio of -232.00, suggesting that the stock may be overvalued relative to its earnings, which could deter value-focused investors.
Vertex Pharmaceuticals Incorporated has experienced fluctuations in analyst ratings, with some firms downgrading their ratings and price targets, which can create uncertainty in the stock's future performance.
The company has a relatively low beta of 0.40, indicating lower volatility compared to the market. While this can be seen as stability, it may also suggest limited growth potential in a bullish market.
Recent changes in institutional holdings, such as Country Trust Bank reducing its stake by 11.1%, may indicate a lack of confidence from some investors, which could impact the stock's performance.

VRTX Forecast - Frequently Asked Questions

: According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Vertex Pharmaceuticals is $505.57, with a high forecast of $586.00 and a low forecast of $407.00.
: 26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 10 hold ratings, 15 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VRTX shares.
: According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 10.14% based on their 12-month stock forecasts.
: Over the previous 90 days, Vertex Pharmaceuticals's stock had 2 upgrades and 2 downgrades by analysts.
: Vertex Pharmaceuticals has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Canaccord Genuity Group, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Royal Bank of Canada, Scotiabank, Stifel Nicolaus, Truist Financial, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Vertex Pharmaceuticals less than other "medical" companies. The consensus rating score for Vertex Pharmaceuticals is 2.65 while the average consensus rating score for "medical" companies is 2.82. Learn more on how VRTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:VRTX) was last updated on 2/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target